Tismanitinmaleimide

Tismanitin maleimide (pamlectabart tismanitin; HDP-101) is a linker-cargo component of an antibody-drug conjugate (ADC) . Tismanitin maleimide is covalently bound to a monoclonal antibody (mAb) through a cleavable linker, forming a targeted anti-cancer therapy. Tismanitin maleimide can be used for research on multiple myeloma[1].

2311860-86-1

Pamlectabart tismanitin ; HDP-101

12352209

Drug-Linker Conjugates for ADC

Antibody-drug Conjugate/ADC Related

Cancer

O=C(C=CC1=O)N1CCC(N[C@@](C(N[C@@](C(NC2=CC=C(CNC(C[C@H](NC([C@@H](NC(CNC([C@@H](NC(CNC([C@@H](NC([C@@H](NC([C@H]3N4C[C@@H](C3)O)=O)[C@H]([C@H](CO)O)C)=O)CC5=C6NC7=C5C=CC=C7)=O)=O)[C@H](CC)C)=O)=O)CS6=O)=O)C4=O)=O)C=C2)=O)([H])C)=O)([H])C(C)C)=O

C61H80N14O18S

1329.44

[1]Butler MS, et al. Natural product-derived compounds in clinical trials and drug approvals. Nat Prod Rep. 2025 Sep 9.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11268/

Peptides

No Development Reported